Drug 'Can Halve Risk of Cancer Returning'
Posted on: Wednesday, 27 April 2005, 18:00 CDT
THOUSANDS of lives could be saved each year by a drug which can stop breast cancer recurring, say U.S.
researchers.
Two trials have shown that Herceptin halves the risk when given at an early stage.
It worked against an a g g r e s s i v e t y p e o f tumour known as HER-2 positive, found in a fifth of the 40,000 breast cancer cases diagnosed in the UK each year.
It is a fast-growing and frequently fatal form of the disease. Each year some 5,500 women with this form of cancer are told the disease has spread.
Herceptin, also known as trastuzumab, is currently used by the NHS for women with advanced disease.
It would have to be reassessed before it could be cleared for the new use.
Laboratory tests can show whether a patient has HER-2 positive breast cancer but surveys show that only around a third of victims are ever tested.
Source: Daily Mail; London (UK)
Related Articles
- New Molecular Pathway For Targeting Cancer, Disease
- Further Testing With Breast-Specific Gamma Imaging (BSGI) Uncovers Additional Cancer in Breast Cancer Patients, Changes Surgical Management
- NCCN Updates Breast Cancer and Breast Cancer Risk Reduction Guidelines
- Aureon Laboratories Introduces Prostate Px(R)+, First Biopsy-Based Test to Predict Prostate Cancer Disease Progression and Recurrence
- Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
- St. Louis Cancer and Breast Institute to Get New AccuBoost System for Breast Cancer
- Analyse the Size of the World's Breast Cancer Disease and Therapy Market
- Use of Hyperthermia Therapy in Treating Primary and Recurrent Breast Cancer Highlights Breast Cancer Congress
- 'Cure' for Cancer of Breast
- Abortion and Breast Cancer Not Linked
 |
 |
User Comments (0)
RSS Feeds